AK157D1 / Akesobio - LARVOL DELTA

A Study of AK157D1 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=243 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

A Study of AK157D1 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=243 | Not yet recruiting | Sponsor: Akeso

First-in-human • New P1 trial • Oncology • Solid Tumor

Akeso…announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) (PRNewswire) - "The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors."

New P1 trial • Oncology • Solid Tumor